Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome
Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome

NCT06050122

Active Not RecruitingPhase 3

Sponsor: Sol-Gel Technologies, Ltd.

Conditions: Gorlin Syndrome

Interventions: Patidegib Topical Gel, Patidegib Topical Gel with no active patidegib

Countries: United States, France, Germany, Italy, Netherlands, Spain, United Kingdom

The aim of this clinical study is to find out how well Patidegib Gel 2% works in preventing new basal cell carcinomas (BCCs) developing on the face of adults with Gorlin syndrome, and how safe Patidegib Gel 2% is to use. People who take part will apply either Patidegib Gel 2% or a Vehicle Gel (with no active drug substance) to their face twice a day for a year (12 months). The number of new BCCs on the face will be compared between those who used Patidegib Gel 2% or Vehicle Gel after 12 months.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria
Key Inclusion Criteria:

1. The subject must be at least 18 years old at the Screening Visit.
2. The subject must be confirmed to have a PTCH1 mutation.
3. The subject must have at least 10 BCCs on the face at Randomization (Baseline/Day 1).
4. The subject must be willing to abstain from application of any non-study topical medication (prescription or over the counter) to their facial skin for the duration of the trial, except as prescribed by the investigator.

Key Exclusion Criteria:

1. The subject has used topical treatment to the face or systemic therapies that might interfere with the evaluation of the study Investigational Product (IP).
2. The subject is known to have hypersensitivity to any of the ingredients in the IP formulation.
3. The subject has uncontrolled systemic disease.
4. The subject has been treated for invasive cancer within the past 5 years excluding chronic lymphocytic leukemia Stage 0, non-melanoma skin cancer, successfully treated melanoma in situ and Stage I melanoma, Stage I cervical cancer, or ductal carcinoma in situ of the breast.
5. Inefficacy of previous Hedgehog inhibitor therapy.
Locations (40)
  • Rogers, Arkansas, United States
  • Fremont, California, United States
  • Los Angeles, California, United States
  • Newport Beach, California, United States
  • Redwood City, California, United States
  • New Haven, Connecticut, United States
  • Tallahassee, Florida, United States
  • Tampa, Florida, United States
  • Chicago, Illinois, United States
  • Baltimore, Maryland, United States
  • Ann Arbor, Michigan, United States
  • New Brighton, Minnesota, United States
  • Saint Joseph, Missouri, United States
  • Verona, New Jersey, United States
  • New York, New York, United States
  • Durham, North Carolina, United States
  • Canton, Ohio, United States
  • Cleveland, Ohio, United States
  • Mayfield Heights, Ohio, United States
  • Oklahoma City, Oklahoma, United States
  • Portland, Oregon, United States
  • Hershey, Pennsylvania, United States
  • Frisco, Texas, United States
  • Houston, Texas, United States
  • Bobigny, France
  • Nantes, France
  • Pierre-Bénite, France
  • Munich, Bavaria, Germany
  • Berlin, Germany
  • Chemnitz, Germany
  • + 10 more on CT.gov